NumFin

Rigel Pharmaceuticals, Inc.

Simbol: RIGL

NASDAQ

1.1

USD

Tržna cena danes

  • -7.4054

    Razmerje P/E

  • 3.7767

    Razmerje PEG

  • 192.92M

    Kapaciteta MRK

  • 0.00%

    Donos DIV

Rigel Pharmaceuticals, Inc. (RIGL) Finančni izkazi

Download
LetniČetrtletno
LinearnoLog
Na grafu so prikazane privzete številke v dinamiki za Rigel Pharmaceuticals, Inc. (RIGL). Prihodki podjetja prikazujejo povprečje 37.295 M, ki je 7.194 % gowth. Povprečni bruto dobiček za celotno obdobje je 21.418 M, ki je 6.122 %. Povprečno razmerje bruto dobička je -1.788 %. Rast čistega dobička za lanskoletno poslovanje podjetja je -0.593 %, kar je enako -0.241 % % v povprečju v celotni zgodovini podjetja.,

LetniČetrtletno
10Y20Y30Y40Y

Bilanca stanja

Če pogledamo fiskalno pot podjetja Rigel Pharmaceuticals, Inc., opazimo povprečno rast sredstev. Zanimivo je, da ta stopnja znaša , kar odraža tako visoke kot tudi padce podjetja. Pri primerjavi četrtletja s četrtletjem se ta številka prilagodi na 0. Pogled nazaj v preteklo leto razkrije skupno spremembo sredstev v višini -0.127. Na področju kratkoročnih sredstev RIGL znaša 99.266 v valuti poročanja. Velik del teh sredstev, natančneje 56.933, je v denarju in kratkoročnih naložbah. V tem segmentu se je ob primerjavi s podatki za preteklo leto spremenil za -0.022%. Dolgoročne naložbe podjetja, ki sicer niso v središču njegovega zanimanja, znašajo 0, če obstajajo, v valuti poročanja. To pomeni razliko v višini 0.000% glede na zadnje obdobje poročanja, kar odraža strateške premike družbe. Dolgoročni profil podjetja kaže skupni dolgoročni dolg v višini 52.658 v valuti poročanja. Ta številka pomeni medletno spremembo v višini 0.458%. Vrednost za delničarje, kot jo prikazuje celotni lastniški kapital, je ovrednotena z vrednostjo -28.644 v valuti poročanja. Letna sprememba tega vidika je 1.104%. Podrobnejši pregled finančnih podatkov podjetja razkrije dodatne podrobnosti. Neto terjatve so ovrednotene na 30.55, zaloge na 5.52, dobro ime pa na 0, če obstaja. Celotna neopredmetena sredstva, če so prisotna, so ovrednotena z vrednostjo 13.88. Obveznosti in kratkoročni dolgovi so -0.37 oziroma {{short_term_deby}}. Celotni dolg je 60.58, neto dolg pa je 27.79. Druge kratkoročne obveznosti znašajo 21.16 in se dodajo k skupnim obveznostim 145.87. Nazadnje se navedena zaloga vrednoti po vrednosti {{preffered_stock}}, če obstaja.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999

balance-sheet.row.cash-and-short-term-investments

242.356.958.2125
57.3
98.1
128.5
115.8
74.8
126.3
143.2
212
298.2
247.6
177.3
133.3
134.5
108.3
104.5
138.2
71.4
46.5
27.3
33.4
53
5.8

balance-sheet.row.short-term-investments

75.0124.133.7106.1
27
75.6
52.2
77.5
57.1
82.8
128
191.1
264.8
229
168.4
118.6
88.5
63.8
56.7
61.4
60.9
36.9
0.8
21.9
4
0

balance-sheet.row.net-receivables

104.2830.640.315.5
16
10.1
4.1
0
0
0.2
5.8
5.8
0
0
0
0
0
0.4
1.4
1.8
0.7
1.3
7.7
1.2
0.7
2.3

balance-sheet.row.inventory

33.495.59.16.6
1.6
1.4
0.9
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-current-assets

22.116.38.37.4
14
9.5
3.5
1.7
1.4
2.5
1.6
2.4
4.2
2.6
2.6
2.6
3.6
2.4
2.2
2.6
2.1
2.3
1.9
2
1
0.3

balance-sheet.row.total-current-assets

402.1999.3115.9154.5
89
119
137
117.4
76.2
129
150.5
220.1
302.5
250.2
179.9
136
138.1
111.1
108
142.6
74.2
50.1
36.9
36.5
54.7
8.5

balance-sheet.row.property-plant-equipment-net

4.8512.811.9
20.6
27.9
1.4
0.9
1.2
1.6
2.5
4.5
5.8
4.9
4.5
2.3
3.6
2.6
3
3.5
2.8
3.5
5.2
8.4
9.3
8.4

balance-sheet.row.goodwill

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

57.1213.914.90
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

57.1213.914.90
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-investments

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

9.093.10.61
0.8
0.7
0.7
0.8
0.8
1.1
1.1
1.5
1.8
2
2.2
2.5
2.2
2.1
2.3
1.6
1.8
1.9
2.3
1.5
0.2
0.2

balance-sheet.row.total-non-current-assets

71.061818.412.9
21.4
28.6
2.1
1.7
1.9
2.7
3.6
6
7.6
6.9
6.8
4.8
5.8
4.7
5.2
5.1
4.6
5.4
7.5
9.9
9.6
8.6

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

473.25117.2134.3167.3
110.4
147.6
139.1
119.1
78.1
131.7
154.1
226.1
310
257.1
186.7
140.7
143.9
115.8
113.2
147.7
78.8
55.5
44.3
46.4
64.3
17.2

balance-sheet.row.account-payables

26.687.122.53.8
3.7
4.2
6.4
2.6
5.6
2.8
1.6
3.9
1.7
1.6
1.4
3.2
6
4.3
2
2.5
1.9
1.4
3.5
2
1.3
0.9

balance-sheet.row.short-term-debt

9.517.91.19.9
8.6
7.3
0
0.3
3.2
3
2.8
0
7.7
0
0.8
1.1
1.3
1
1.3
1.1
1.3
2.3
3.4
3.2
3
2.2

balance-sheet.row.tax-payables

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

233.2752.740.420.7
30.5
29
0
0
0.2
3.5
6.5
0
0
0
0
0.9
2.1
0.8
1.1
1.1
0.8
1.2
2.3
4.2
6.2
5.5

Deferred Revenue Non Current

0000
0
1.4
1.4
0
0
6.5
0
0
0
9.3
9.1
12.1
0
0
0
2.8
4.2
0.5
2.1
2.2
0.4
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

119.6921.228.147.3
25.5
21.5
20.3
15.7
17
14.6
12.4
6.4
2.1
9.8
9.9
14.6
13.7
0.6
4.9
4.5
4.4
2.2
3.5
1.8
1.4
6.5

balance-sheet.row.total-non-current-liabilities

395.0292.682.773.4
35.5
35.5
1.5
0.1
0.5
6.6
11.9
7.5
8.7
9.4
9.2
13.1
15.5
17.5
14.8
15.4
15.1
7.5
4.5
7.3
7.2
6.9

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

4.4612.110.7
19.3
26.5
0
0.3
3.5
6.5
9.3
0
0
0
0.8
1.9
2.1
0.8
1.1
1.1
0.8
1.2
2.3
4.2
5.8
0

balance-sheet.row.total-liab

586.1145.9147.9137
76.4
93.8
29.2
18.5
23.1
40.4
25.9
17.8
20.9
21
20.6
30.9
39.7
33.6
26
39.1
26.5
15.6
18.9
17.5
15.3
16.4

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

0.70.20.20.2
0.2
0.2
0.2
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.retained-earnings

-5614.43-1407.5-1382.5-1323.9
-1306
-1276.2
-1209.3
-1138.9
-1060.9
-991.6
-940.2
-849.3
-760.2
-661.4
-575.4
-613.3
-501.8
-369.4
-295.2
-257.5
-212.3
-156
-114.8
-77.8
-54
-28.6

balance-sheet.row.accumulated-other-comprehensive-income-loss

-0.060-0.2-0.1
0
0
0
-0.1
0
0
0
0
0.1
0
0
0
0.4
0.2
0
-0.1
-0.3
-0.2
-0.8
-2.4
-5.8
-5.8

balance-sheet.row.other-total-stockholders-equity

5500.941378.71368.81354.2
1339.8
1329.9
1319.1
1239.4
1115.8
1083
1068.3
1057.4
1049.2
897.5
741.6
723.2
605.5
451.4
382.4
366.2
264.8
196.2
141
109.1
108.7
35.2

balance-sheet.row.total-stockholders-equity

-112.85-28.6-13.630.4
34
53.8
109.9
100.6
55
91.4
128.2
208.3
289.1
236.1
166.1
109.9
104.2
82.2
87.2
108.6
52.3
40
25.4
28.9
49
0.8

balance-sheet.row.total-liabilities-and-stockholders-equity

473.25117.2134.3167.3
110.4
147.6
139.1
119.1
78.1
131.7
154.1
226.1
310
257.1
186.7
140.7
143.9
115.8
113.2
147.7
78.8
55.5
44.3
46.4
64.3
17.2

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

-112.85-28.6-13.630.4
34
53.8
109.9
100.6
55
91.4
128.2
208.3
289.1
236.1
166.1
109.9
104.2
82.2
87.2
108.6
52.3
40
25.4
28.9
49
0.8

balance-sheet.row.total-liabilities-and-total-equity

473.25---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

75.0124.133.7106.1
27
75.6
52.2
77.5
57.1
82.8
128
191.1
264.8
229
168.4
118.6
88.5
63.8
56.7
61.4
60.9
36.9
0.8
21.9
4
0

balance-sheet.row.total-debt

242.7860.641.630.6
39.1
36.3
0
0.3
3.5
6.5
9.3
0
0
0
0.8
1.9
3.4
1.8
2.4
2.2
2.1
3.5
5.7
7.4
9.1
7.7

balance-sheet.row.net-debt

75.4827.817.111.7
8.7
13.8
-76.3
-38
-14.2
-37
-5.9
-20.9
-33.5
-18.6
-8.1
-12.8
-42.6
-42.7
-45.4
-74.6
-8.4
-6.1
-20.8
-4.1
-39.9
1.8

Izkaz denarnih tokov

V zadnjem obdobju se je v finančnem okolju Rigel Pharmaceuticals, Inc. opazno spremenil prosti denarni tok, ki se je spremenil v 0.720. Podjetje je nedavno povečalo svoj osnovni kapital z izdajo 1.05, kar kaže na razliko 0.575 v primerjavi s prejšnjim letom. Družba je pri naložbenju porabila neto denarna sredstva v višini -4297000.000 v valuti poročanja. To je premik za -1.059 v primerjavi s prejšnjim letom. V istem obdobju je družba zabeležila 1.24, 0 in -17.32, ki so pomembne za razumevanje naložbenih in odplačilnih strategij podjetja. Družba je pri financiranju porabila 0.000, pri čemer je razlika v primerjavi z letom prej znašala 0.000. Poleg tega je podjetje namenilo 0 za izplačilo dividend svojim delničarjem. Hkrati je izvajalo tudi druge finančne manevre, imenovane 34.64, ki so prav tako pomembno vplivali na denarni tok v tem obdobju. Te sestavine skupaj tvorijo celovito sliko finančnega stanja podjetja in strateškega pristopa k upravljanju denarnih tokov.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999

cash-flows.row.net-income

-25.09-25.1-58.6-17.9
-29.7
-66.9
-70.5
-78
-69.2
-51.5
-90.9
-89
-98.8
-86
37.9
-111.5
-132.3
-74.3
-37.6
-45.3
-56.3
-41.2
-37
-23.8
-25.4
-12.4

cash-flows.row.depreciation-and-amortization

1.241.211.2
0.7
0.7
0.6
0.5
0.9
1.4
2.4
2.6
2.4
2
1.3
1.4
1.4
1.3
1.4
1.2
2.4
3.2
5.8
6.8
7.6
1.9

cash-flows.row.deferred-income-tax

3.99-10.600.3
0
0
0
-1.1
0
0
-0.1
0
0
86
0
0
0
-11.7
-12.6
0
-0.1
-0.5
-1
-2.6
-2.7
0

cash-flows.row.stock-based-compensation

8.818.812.49.5
7.3
9.1
7.7
6
7.3
7.4
9.8
7.2
12.6
13.2
16.4
13.4
0
11.7
12.6
0
0.1
0.5
1
2.6
4.9
0

cash-flows.row.change-in-working-capital

9.529.5-299.7
-30.3
16.7
4.1
-5.4
-15.8
19.3
-0.2
-6.8
-1.4
1.5
-8.9
-6.1
3.6
9
-12.2
11
13.3
4.7
-3.1
1.6
-1.2
0.9

cash-flows.row.account-receivables

9.779.8-24.80.5
-5.9
-6
-4.1
0
0.2
5.5
0
-5.8
0
0
0
0
0
1.1
-0.1
-1.1
0.5
0.3
-0.3
-0.5
1.7
0

cash-flows.row.inventory

1.171.2-2.4-4.9
-0.1
-0.4
-0.8
0
2.1
0.8
0
1.4
0
0
0
0
0
1.8
1.3
-107.4
-50.6
-35.7
-26.8
-24.9
-50
0

cash-flows.row.account-payables

-0.37-0.43.80
-0.3
-2.2
3.8
-2.9
2.8
1.1
-2.3
2.2
0.1
0.2
-1.8
-2.8
0
2.4
-0.5
0.6
0.6
-2.1
1.5
0.6
0.4
0

cash-flows.row.other-working-capital

-1.06-1.1-5.614.1
-24
25.3
5.3
-2.5
-20.9
11.8
2.1
-4.6
-1.5
1.3
-7.1
-3.2
3.6
3.8
-12.9
118.9
62.8
42.1
22.5
26.4
46.6
0.9

cash-flows.row.other-non-cash-items

-4.2110.40.53.1
-0.1
-1.1
-0.8
0.5
0.8
-0.1
9.3
0
0
-86
0
0
23.8
11.7
12.6
-2.1
2.5
0.9
-0.2
-0.5
5.3
1.7

cash-flows.row.net-cash-provided-by-operating-activities

-5.74000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-15.13-15-0.5-0.6
-1.3
-1.5
-1.1
-0.2
-0.8
-0.5
-0.4
-1.2
-3.4
-2.3
-3.6
-0.1
-2.5
-0.9
-0.9
-1.8
-1.5
-1.2
-1.6
-3.2
-3.6
-7.1

cash-flows.row.acquisitions-net

0.260.30.90.6
1.3
1.5
1.1
0
0
0
0
1.2
3.4
2.3
3.6
0.1
0
0
0
0
0
0
-25
0
0
0

cash-flows.row.purchases-of-investments

-31.33-31.2-28.9-141.5
-81.7
-145.3
-78
-116.9
-103.1
-151.8
-218.6
-308.8
-475.4
-476
-266.1
-169.9
-194.6
-134.4
-85.2
-89.6
-96.4
-42.1
-26.7
-47.5
-4
0

cash-flows.row.sales-maturities-of-investments

41.6541.6101.262
130.4
123.1
104.1
96.8
128.7
196.9
281.7
382.4
439.7
415.5
216.2
139.4
170.1
127.5
90
89.2
72.2
6
47.8
29.6
0
0

cash-flows.row.other-investing-activites

3.2300-0.6
-1.3
-1.5
-1.1
0.7
0.1
0.1
0.2
-1.2
-3.4
-2.3
-3.6
-0.1
0
0
0.1
0
0
0.1
25
0
0
0

cash-flows.row.net-cash-used-for-investing-activites

-4.3-4.372.8-80
47.5
-23.7
25
-19.5
24.9
44.6
62.9
72.4
-39.1
-62.8
-53.4
-30.7
-27
-7.8
3.9
-2.2
-25.8
-37.3
19.5
-21.1
-7.6
-7.1

cash-flows.row.debt-repayment

-20.93-17.3-4.4-57.9
-10
-9.8
0
0
0
0
0
0
0
-0.8
-1.1
-1.4
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-issued

1.0512.14.8
2.6
1.6
67.2
114.2
23.6
5.3
1.2
1.1
139.1
142.8
2
103.6
130.4
57.4
2.8
103.5
66.2
54.6
31.8
0.9
61.3
6

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-financing-activites

36.9334.68.9115.8
19.9
19.6
4.7
3.5
1.6
1.8
0
0
0
0
0
0
1.6
-0.6
0
0.1
-1.4
-1.8
-1.7
-1.3
1.1
5.3

cash-flows.row.net-cash-used-provided-by-financing-activities

18.3718.46.562.7
12.6
11.4
71.9
117.7
25.2
7.1
1.2
1.1
139.1
142
0.8
102.2
132
56.8
2.8
103.6
64.8
52.8
30.1
-0.4
62.4
11.3

cash-flows.row.effect-of-forex-changes-on-cash

-1.01000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

8.338.35.6-11.5
7.9
-53.8
38
20.7
-25.8
28.3
-5.7
-12.6
14.9
9.8
-5.8
-31.3
1.5
-3.2
-29.1
66.3
0.9
-16.9
15
-37.5
43.2
-3.7

cash-flows.row.cash-at-end-of-period

167.332.824.518.9
30.4
22.5
76.3
38.3
17.6
43.5
15.2
20.9
33.5
18.6
8.9
14.7
46
44.5
47.7
76.8
10.5
9.6
26.5
11.5
49
5.8

cash-flows.row.cash-at-beginning-of-period

158.9724.518.930.4
22.5
76.3
38.3
17.6
43.5
15.2
20.9
33.5
18.6
8.9
14.7
46
44.5
47.7
76.8
10.5
9.6
26.5
11.5
49
5.8
9.5

cash-flows.row.operating-cash-flow

-5.74-5.7-73.85.9
-52.2
-41.5
-58.8
-77.6
-75.9
-23.4
-69.8
-86.1
-85.2
-69.4
46.7
-102.8
-103.5
-52.2
-35.8
-35.2
-38.2
-32.4
-34.5
-16
-11.6
-7.8

cash-flows.row.capital-expenditure

-15.13-15-0.5-0.6
-1.3
-1.5
-1.1
-0.2
-0.8
-0.5
-0.4
-1.2
-3.4
-2.3
-3.6
-0.1
-2.5
-0.9
-0.9
-1.8
-1.5
-1.2
-1.6
-3.2
-3.6
-7.1

cash-flows.row.free-cash-flow

-20.88-20.7-74.25.3
-53.4
-43
-59.9
-77.7
-76.7
-24
-70.2
-87.3
-88.6
-71.7
43.2
-102.9
-106
-53.1
-36.7
-37
-39.7
-33.7
-36.2
-19.2
-15.2
-14.9

Vrstica izkaza poslovnega izida

Prihodki Rigel Pharmaceuticals, Inc. so se v primerjavi s prejšnjim obdobjem spremenili za -0.028%. Bruto dobiček podjetja RIGL znaša 109.77. Odhodki iz poslovanja podjetja so 130.26 in so se v primerjavi s prejšnjim letom spremenili za -24.583%. Odhodki za amortizacijo znašajo 1.24, kar je 0.810% sprememba glede na zadnje obračunsko obdobje. Stroški poslovanja so sporočeni v višini 130.26, ki kaže -24.583% spremembo glede na preteklo leto. Stroški prodaje in trženja znašajo 0, kar pomeni 0.000% spremembo v primerjavi s preteklim letom. EBITDA na podlagi zadnjih podatkov znaša 0 in predstavlja 0.622% rast v primerjavi s preteklim letom. Prihodki iz poslovanja so -20.49, ki kažejo -0.622% spremembo v primerjavi s preteklim letom. Sprememba čistih prihodkov je -0.593%. Čisti prihodki v zadnjem letu so znašali -25.09.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999

income-statement-row.row.total-revenue

116.88116.9120.2149.2
108.6
59.3
44.5
4.5
20.4
28.9
8.3
7.2
2.3
4.8
125
0.8
0
12.6
33.5
16.5
4.7
11.1
15.8
15.3
13.2
9

income-statement-row.row.cost-of-revenue

7.117.11.71.1
0.9
0.9
0.3
46.3
63.4
62.8
67.7
75.3
78.8
0
0
0
0
0
0
0
0
0
0
0
-7.6
-1.9

income-statement-row.row.gross-profit

109.77109.8118.5148.2
107.7
58.4
44.2
-41.8
-43.1
-33.9
-59.4
-68.2
-76.5
4.8
125
0.8
0
12.6
33.5
16.5
4.7
11.1
15.8
15.3
20.8
10.9

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

24.52---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

26.31---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

001.33.5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7.6
1.9

income-statement-row.row.operating-expenses

130.26130.3172.7157.1
136.7
127.5
116.9
84.1
84.4
80.6
99.5
94.9
101.6
91.1
89.7
111.6
136.7
92.1
76.5
64.4
61.6
51.9
52.8
40.3
46.3
23

income-statement-row.row.cost-and-expenses

137.37137.4174.5158.2
137.6
128.4
117.2
84.1
84.4
80.6
99.5
94.9
101.6
91.1
89.7
111.6
136.7
92.1
76.5
64.4
61.6
51.9
52.8
40.3
38.7
21.1

income-statement-row.row.interest-income

2.272.30.70
0.6
2.5
2.2
0.9
0.4
0.2
0.2
0.4
0.5
0.4
0.3
0.6
4.4
5.5
5.7
2.9
1
0.4
0.9
2
1.1
0

income-statement-row.row.interest-expense

6.876.93.74.9
1.4
0.3
0
0
0
0
0
0
0
0
0.1
0.2
0.2
0.2
0.3
0.3
0.3
0.6
0.9
0.8
0.9
0

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-4.6-4.6-4.3-8.3
-0.8
2.2
2.2
0.7
-5.7
0.1
0.1
-1.7
0.5
0.4
2.4
-1.1
4.3
5.3
5.4
2.7
0
-0.2
0
1.2
0.1
0

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

001.33.5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7.6
1.9

income-statement-row.row.total-operating-expenses

-4.6-4.6-4.3-8.3
-0.8
2.2
2.2
0.7
-5.7
0.1
0.1
-1.7
0.5
0.4
2.4
-1.1
4.3
5.3
5.4
2.7
0
-0.2
0
1.2
0.1
0

income-statement-row.row.interest-expense

6.876.93.74.9
1.4
0.3
0
0
0
0
0
0
0
0
0.1
0.2
0.2
0.2
0.3
0.3
0.3
0.6
0.9
0.8
0.9
0

income-statement-row.row.depreciation-and-amortization

1.631.20.70
0.6
2.5
0.6
0.5
0.9
1.4
2.4
2.6
2.4
2
1.3
1.4
1.4
1.3
1.4
1.2
2.4
3.2
5.8
6.8
7.6
1.9

income-statement-row.row.ebitda-caps

-17.28---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-20.49-20.5-54.2-9
-29
-69.1
-72.7
-79.6
-69.7
-51.7
-91.2
-89.5
-99.4
-86.4
35.3
-112
-136.7
-79.5
-43
-47.9
-56.9
-40.8
-37
-25
-25.5
-12.1

income-statement-row.row.income-before-tax

-25.09-25.1-58.6-17.3
-29.7
-66.9
-70.5
-78
-69.2
-51.5
-90.9
-89
-98.8
-86
37.9
-111.6
-132.4
-74.3
-37.6
-45.3
-56.3
-41.2
-37
-23.8
-25.4
0

income-statement-row.row.income-tax-expense

2.392.330.6
0.6
-0.3
2.2
-2.1
4.3
-1.7
-2.7
0
-2.4
0.4
0.1
-0.1
-0.1
0
0
0
-0.6
0.4
0
0
0
0.3

income-statement-row.row.net-income

-25.9-25.1-61.6-17.9
-30.4
-66.5
-70.5
-78
-69.2
-51.5
-90.9
-89
-98.8
-86
37.9
-111.5
-132.3
-74.3
-37.6
-45.3
-56.3
-41.2
-37
-23.8
-25.4
-12.4
Podobne delnice
Morda vas zanima tudi:
MRVI
Maravai LifeSciences Holdings, Inc..
7.7 USD
NASDAQ
CMRA
Comera Life Sciences Holdings, Inc..
0.0361 USD
NASDAQ
T5O.DE
CytoTools AG.
0.488 EUR
XETRA
HBC.OL
Hofseth BioCare ASA.
2.09 NOK
OSL
PPBT
Purple Biotech Ltd..
0.67 USD
NASDAQ
SPHRF
Starpharma Holdings Limited.
0.0774 USD
PNK

Pogosto zastavljeno vprašanje

Kaj je Rigel Pharmaceuticals, Inc. (RIGL) skupna sredstva?

Rigel Pharmaceuticals, Inc. (RIGL) skupna sredstva so 117225000.000.

Kakšen je letni prihodek podjetja?

Letni prihodki so 63926000.000.

Kolikšna je stopnja dobička podjetja?

Dobiček podjetja je 0.939.

Kakšen je prosti denarni tok podjetja?

Prosti denarni tok je -0.120.

Kolikšna je neto stopnja dobička podjetja?

Čista stopnja dobička je -0.222.

Kolikšni so skupni prihodki podjetja?

Celotni prihodki so -0.175.

Kaj je Rigel Pharmaceuticals, Inc. (RIGL) čisti dobiček (čisti dobiček)?

Čisti dobiček (čisti prihodek) je -25091000.000.

Kolikšen je skupni dolg podjetja?

Skupni dolg je 60579000.000.

Kolikšni so stroški poslovanja?

Stroški poslovanja so 130263000.000.

Kolikšno je število denarnih sredstev podjetja?

Denarna sredstva podjetja so 32786000.000.